T he subject of t h i s c a s e report is a gentleman in his 4 0 s w i t h a n e s t a b l i s h e d d i a g n o s i s o f paranoid schizophrenia. Over a period of several months he was diagnosed with NMS on three occasions and later had two further discrete episodes that were in keeping with malignant catatonia. The first presentation was suggestive of NMS. The patient had been taking flupentixol decanoate 400mg depot injection every two weeks for the past eight months and was also taking risperidone 4mg daily and sertraline, which he had been on for about two months. He was found immobile on the floor of his home one week after his depot had been administered. He had been incontinent of urine and had not eaten or taken his oral medication for the preceding two days.
On examination the patient was delirious with mild cogwheel rigidity and a low grade pyrexia. He was admitted to a medical ward, where a diagnosis of urinary sepsis was made and he was treated with intravenous antibiotics and fluids. Both NMS and serotonin syndrome were considered due to an elevated creatinine kinase (CK) of 20 972 U/L, for this reason the antidepressant and risperidone were discontinued. In spite of this, the medical team were confident that the raised CK was as a result of urinary sepsis and prolonged immobility, rather than NMS. He was administered depot antipsychotic medication within two weeks of this presentation. Six days later, he developed symptoms of delirium, diaphoresis, tremor and muscle rigidity. His CK was raised at 1559 U/L (having normalised between episodes). He was diagnosed with NMS, which was treated with intravenous fluids and his depot was discontinued. He was commenced on oral quetiapine about 10 days later, after the CK level had returned to the normal range.
Two weeks after initiating quetiapine he presented again with diaphoresis, mild pyrexia, tremor, muscle rigidity and tachycardia. He was described as perplexed but not delirious. His CK was measured at 8000 U/L, having remained in the normal range one week after initiation. He was treated on a medical ward for NMS with intravenous fluids and all neuroleptics were discontinued.
Within seven days, whilst completely medication free, he p r e s e n t e d w i t h p e r i o d s o f 
Use of injectable antipsychotic medication is a known risk factor for NMS, 1,3 therefore the depot was discontinued following the second episode and a second generation antipsychotic was chosen to replace it due to lower risk of mortality from NMS. 4 One condition, or two? Due to the differing symptomatology of the NMS episode and the malignant catatonia episode, this case could demonstrate that the two conditions are separate entities. It could also be considered that due to multiple episodes of both syndromes appearing in this case that there may be a similar underlying pathology and the two conditions could be considered to be on a spectrum. The evidence supporti n g b o t h p o s s i b i l i t i e s a r e presented in Table 2 .
Investigations
Elevated CK levels may have limited usefulness in terms of distinguishing between these two conditions. A rise in CK has been widely reported in NMS and also occurs in catatonic patients. 15 Although NMDA receptor autoantibodies tested negative in the above case, there have been cases of patients with both catatonia and NMS testing positive, 16 which has important implications for management.
Rickards et al. recommended screening for NMDA receptor
Evidence favouring NMS and malignant catatonia being separate diagnostic entities Evidence against NMS and malignant catatonia being separate diagnostic entities
Symptomatology
• Muscular rigidity is a consistent feature of NMS whereas literature from the preneuroleptic era suggested that muscular rigidity in malignant catatonia appeared as a later sign 5 • Different mode of onset of the two conditions: malignant catatonia often beginning with psychotic excitement leading to fever, exhaustion and death, whereas NMS often begins with severe extrapyramidal symptoms 6 • Similar signs, symptoms and response to treatment, 8, 9 individuals have been found to meet the diagnostic criteria for both conditions simultaneously 10 • Several reported cases of catatonia immediately preceding NMS, 11,12,13 which may suggest a common neurological basis for both conditions and that catatonia may sensitise individuals to the development of NMS 12 or may be a risk factor for the development of NMS 14 Proposed mechanism of action
• Symptoms of NMS have been hypothesised to arise from D2 blockade in the striatum and abnormal corticalsubcortical modulation. This is in contrast to catatonic symptoms arising from right posterior parietal and lateral orbitofrontal dysfunction 7
• Catatonia is a result of massive dopamine blockade due to excessive hyperstimulation in psychotic illness, whilst NMS is caused by a similar blockade but triggered by neuroleptics 12 18 However, it has also been reported that as many as 87% may be successfully rechallenged with an antipsychotic following an episode of NMS. 2 A longer washout period has been found to increase the likelihood of success of rechallenge. 2, 18 In one study of patients with a history of NMS, six out of nine patients were successfully treated with clozapine without any further complications. 19 
Clozapine induced NMS
It is important to consider that NMS induced by clozapine may present with fewer clinical features, 20 in particular, less rigidity and other extrapyramidal symptoms. Therefore clozapi n e -i n d u c e d N M S m a y b e particularly difficult to detect given that tachycardia, blood p r e s s u r e d i s t u r b a n c e a n d pyrexia are common during clozapine initiation due to the effects of clozapine itself or medical complications. 4 
Conclusion
This case demonstrates differing symptomatology of episodes of NMS and malignant catatonia, suggesting the two could be separate conditions. However, it does appear that one condition may increase susceptibility to developing the other.
The literature suggests that patients with catatonia appear t o b e a t a h i g h e r r i s k o f developing NMS and this case raises the question as to whether the reverse also holds true. This has implications for use of antipsychotics in catatonic patients and raises the question of whether there is a need for a 'symptom-free period' similar to the antipsychotic washout period for NMS before commencing an antipsychotic.
In similar complex cases NMDA receptor autoantibodies should be measured to rule out an underlying organic pathology.
There is currently little evidence to guide management of psychosis in a patient who has had multiple episodes of NMS, it seems that clozapine may be the most appropriate choice.
Due to the potential difficulties in detecting NMS in clozapine patients, we would suggest cautious dose titration with regular measurement of CK during the initiation period.
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